Anti-BCMA Neutralizing Antibody, Mouse IgG1 (recommended for neutralizing assay)

用户评价
货号-规格
价格
Qty.
BCA-M43-100ug
¥3150.00
BCA-M43-1mg (500ug X 2)
¥20790.00
合计0件 产品金额¥ 0

产品详情

  • 抗体来源(Source)

    Anti-BCMA Neutralizing Antibody, Mouse IgG1 is a Mouse monoclonal antibody recombinantly expressed from HEK293 cells.

  • 种属(Species)

    Mouse

  • 亚型(Isotype)

    Mouse IgG1 | Mouse Kappa

  • 偶联(Conjugate)

    Unconjugated

  • 抗体类型(Antibody Type)

    Recombinant Monoclonal

  • 种属反应性(Reactivity)

    Human

  • 免疫原(Immunogen)

    BCMA.

  • 特异性(Specificity)

    The product is specific for Human BCMA Protein extracellular, and can inhibit the interaction between BCMA and BAFF (IC50= 4.877 μg/mL), BCMA and APRIL (IC50= 4.624 μg/mL). It also has cross reactivity with Cynomolgus & Mouse BCMA protein.

  • 应用(Application)

    Application
    Recommended Usage
    ELISA
    0.5-80 ng/mL
  • 纯度(Purity)

    95% as determined by SDS-PAGE.

  • 纯化(Purification)

    Protein A purified / Protein G purified

  • 制剂(Formulation)

    Lyophilized from 0.22 μm filtered solution in Tris with Glycine, Arginine and NaCl, pH7.5 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • 重构方法(Reconstitution)

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • 存储(Storage)

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. 4-8°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • 质量管理控制体系(QMS)

    1. 质量管理体系(ISO, GMP)
    2. 质量优势
    3. 质控流程

推荐产品

数据展示

  • 电泳(SDS-PAGE)

    BCMA SDS-PAGE

    Anti-BCMA Neutralizing Antibody, Mouse IgG1 on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 95%.

  • 活性(Bioactivity)-ELISA

     BCMA ELISA

    Immobilized Human BCMA Protein, His Tag (Cat. No. BCA-H522y) at 2 μg/mL (100 μL/well) can bind Anti-BCMA Neutralizing Antibody, Mouse IgG1 (Cat. No. BCA-M43) with a linear range of 0.2-6 ng/mL (QC tested).

    Protocol
  •  BCMA ELISA

    Immobilized Human BCMA, His Tag (Cat. No. BCA-H522y) at 2 μg/mL (100 μL/well) can bind pre-mixed increasing concentrations of Anti-BCMA Neutralizing Antibody, Mouse IgG1 (Clone: AM43, Cat. No. BCA-M43) and 0.05 μg/mL (100 μL/well) Biotinylated Human APRIL, Fc,Avitag (Cat. No. APL-H82F5) with a half maximal inhibitory concentration (IC50) of 17.03 μg/mL (Routinely tested).

    Protocol
  •  BCMA ELISA

    Immobilized Human BCMA, His Tag (Cat. No. BCA-H522y) at 2 μg/mL (100 μL/well) can bind pre-mixed increasing concentrations of Anti-BCMA Neutralizing Antibody, Mouse IgG1 (Clone: AM43, Cat. No. BCA-M43) and 0.01 μg/mL (100 μL/well) Biotinylated Human BAFF, His,Avitag (Cat. No. BAF-H82Q2) with a half maximal inhibitory concentration (IC50) of 14.79 μg/mL (Routinely tested).

    Protocol
  • 活性(Bioactivity)-SPR

     BCMA SPR

    Anti-BCMA Neutralizing Antibody, Mouse IgG1 (Clone: AM43, Cat. No. BCA-M43) captured on CM5 chip via anti-mouse antibodies surface can bind Human BCMA, His Tag (Cat. No. BCA-H522y) with an affinity constant of 0.388 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

    Protocol

用户评价
发表评论

背景介绍

Tumor necrosis factor receptor superfamily member 17 (TNFRSF17) is also known as B-cell maturation protein (BCMA), CD antigen CD269, which is a member of the TNF-receptor superfamily. TNFRSF17 contains one TNFR-Cys repeat. TNFRSF17 is expressed in mature B-cells, but not in T-cells or monocytes. TNFRSF17 is receptor for TNFSF13B/BLyS/BAFF and TNFSF13/APRIL. TNFRSF17 promotes B-cell survival and plays a role in the regulation of humoral immunity. TNFRSF17 can activate NF-kappa-B and JNK.

前沿进展

 
药物研发进展
  • 英文全称:

    B-cell maturation protein

  • 中文全称:

    B细胞成熟蛋白

  • 种类:

  • 上市药物数量:

    7 详情

  • 临床药物数量:

    117 详情

  • 最高研发阶段:

    临床三期

联系我们
项目合作
查看更多项目
实验案例分析
查看更多案例分析
  • 产品基础信息
  • 产品详情
  • 推荐产品
  • 数据展示
  • 用户评价
  • 背景介绍